Clinical trial
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA…
NCT00408278 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00408278 |
|---|---|
| Title | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) |
| Official title | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance… |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Promyelocytic Leukemia |
| Intervention type | Drug |
| Interventions | ATRA, Idarubicina, Mitoxantrone, ARA-C |
| Enrollment | 300 |
| Start date | Jul 1, 2005 |
| Primary completion | Apr 1, 2012 |
| Completion | Dec 1, 2013 |
| First posted | Dec 6, 2006 |
| Last update posted | Oct 28, 2014 |
| Countries | Poland, Spain, Uruguay |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: